De mest almindelige bivirkninger, opstået under behandling, i kliniske forsøg var reversibel kvalme (20%) og opkastning (14%), som ofte viste sig tidligt (på 1. - 2. behandlingsdag) og som generelt var milde eller moderate i sværhedsgrad.
In clinical trials, the most common drug-related treatment emergent adverse reactions were reversible nausea (20%) and vomiting (14%), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity.